Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities.  Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.

Biotechnology

Symphogen

Christophe Thurieau

Heidi Rønnest

Pia Holm Olesen

Malin Carlsson

Michael Herbst

Mads Laustsen

Ivan Horak

Dorthe Sandager Bilde

Rikke Bolding Jensen

Carsten Helle Højgaard

Michael Rasmussen

Claus Haase

The Scientific Team at Symphogen is dedicated to advancing oncology treatments through rigorous research and development. Comprised of experts in monoclonal antibody (mAb) technologies, they focus on creating and validating differentiated mAb and mAb mixture product candidates. The team collaborates on everything from target biology and cell culture to analytical coordination and drug formulation, aiming to deliver precision-medicine solutions for biomarker-selected patient populations.

Scientific Team

Laboratory Team

Leadership Team

Scientific Team

About

Team members

Other teams at Symphogen

Laboratory Team

Leadership Team